News | Radiopharmaceuticals and Tracers | May 13, 2016

Blue Earth Diagnostics Opens U.S. Office, Expands Management Team

Massachusetts office will provide support for development and commercialization of PET imaging agent pending FDA approval

Blue Earth Diagnostics, U.S. headquarters, management expansion, PET imaging agent

May 13, 2016 — Blue Earth Diagnostics, a molecular imaging diagnostics company, announced it has established operations in the United States in Burlington, Mass. The company develops and commercializes innovative positron emission tomography (PET) imaging products that address unmet needs in cancer.

The Massachusetts headquarters will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F-18, the company’s PET imaging agent currently under Priority Review with the U.S. Food and Drug Administration (FDA).

The company also announced the creation of key appointments for Blue Earth Diagnostics Inc.:  Michael W. Heslop, as president; Peter Gardiner, MB ChB, MRCP, FFPM, as vice president, medical affairs; Bradley K. Pounds as vice president, sales, U.S.; David Pendleton, vice president, marketing; Christa Dhimo, vice president, strategy & execution, U.S.; and Priscilla Harlan, vice president, corporate communications.

Blue Earth Diagnostics Inc. is a wholly-owned subsidiary of U.K.-based Blue Earth Diagnostics Ltd.

For more information: www.blueearthdiagnostics.com

Related Content

Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...